doi: 10.1038/s41571-019-0177-5 95 BeierCPSchmidCGorliaTKleinletzenbergerCBeierDGrauerOet al
Seek prompt medical attention if you experience any of the following: Severe or worsening pain, warmth, or swelling at the injection site, which may suggest infection Signs of an allergic reaction: rash, urticaria, facial swelling, difficulty breathing, or anaphylaxis Persistent or severe abdominal pain, which may indicate pancreatitis Right upper quadrant pain, fever, or jaundice, which may indicate gallbladder disease (e.g., cholelithiasis or cholecystitis) a recognised risk with incretin-class therapies Signs of dehydration from persistent vomiting or diarrhoea: reduced urine output, dizziness, or feeling faint on standing this may indicate acute kidney injury and requires urgent assessment Rapid heart rate, dizziness, or fainting Symptoms of hypoglycaemia (particularly if taking concomitant insulin or sulphonylureas): shakiness, sweating, confusion, or palpitations Any new or worsening visual symptoms, particularly if you have diabetes, as rapid improvement in blood glucose control has been associated with worsening of diabetic retinopathy in some patients [7] [8] In the UK, patients experiencing a severe or life-threatening reaction should call 999
Avoid high-fat foods: Because GLP-1s slow digestion, heavy, greasy, or fried foods sit in the stomach for a very long time, which is a recipe for nausea and reflux
Milestone recognition: Week 12 represents completion of dose escalation phase
